CareDx Discusses AlloHeme Clinical Validation Data and Launch Timeline for AML and MDS Post-Cell Therapy

CareDx, Inc. (CDNA) is discussing AlloHeme clinical validation data review and launch timeline in AML and MDS post-cell therapy. The company plans to lead in precision medicine for cell therapy. CareDx will continue to generate revenue and increase commercial success through its testing services, products, and digital solutions. The outcome of clinical trial collaborations and registry studies is uncertain.